(12) STANDARD PATENT (11) Application No. **AU 2001279757 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
Novel heteroaryl derivatives and the use thereof as pharmaceuticals

(51)[7] International Patent Classification(s)
C07D 215/50 **A61K 031/47**
A61P 035/00

(21) Application No: **2001279757** (22) Date of Filing: **2001.07.18**

(87) WIPO No: **WO02/08192**

(30) Priority Data

(31) Number	(32) Date	(33) Country
10035928	**2000.07.21**	**DE**

(43) Publication Date: **2002.02.05**
(43) Publication Journal Date: **2002.05.02**
(44) Accepted Journal Date: **2005.05.26**

(71) Applicant(s)
Zentaris GmbH

(72) Inventor(s)
Kutscher, Bernhard; Nickel, Bernd; Schmidt, Jurgen; Gunther, Eckhard; Emig, Peter

(74) Agent / Attorney
Spruson & Ferguson, Level 35 St Martins Tower 31 Market Street, Sydney, NSW, 2000

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum
Internationales Büro

(43) Internationales Veröffentlichungsdatum
31. Januar 2002 (31.01.2002)

PCT

(10) Internationale Veröffentlichungsnummer
WO 02/08192 A1

(51) Internationale Patentklassifikation[7]: C07D 215/50, A61K 31/47, A61P 35/00

(21) Internationales Aktenzeichen: PCT/EP01/08261

(22) Internationales Anmeldedatum: 18. Juli 2001 (18.07.2001)

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:
100 35 928.0 21. Juli 2000 (21.07.2000) DE

(71) Anmelder: ZENTARIS AG [DE/DE]; Weismüllerstrasse 45, 60314 Frankfurt (DE).

(72) Erfinder: EMIG, Peter; Ludwig-Erhard-Strasse 22, 63486 Bruchköbel (DE). GÜNTHER, Eckhard; Wingertstrasse 176, 63477 Maintal (DE). SCHMIDT, Jürgen; Am Roggersberg 20, 88690 Uhldingen-Mühlhofen (DE). NICKEL, Bernd; Alleestrasse 35, 64367 Mühltal (DE). KUTSCHER, Bernhard; Stresemannstrasse 9, 63477 Maintal (DE).

(81) Bestimmungsstaaten *(national)*: AU, BG, BR, BY, CN, CO, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA.

(84) Bestimmungsstaaten *(regional)*: eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Veröffentlicht:
— *mit internationalem Recherchenbericht*

Zur Erklärung der Zweibuchstaben-Codes und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.

(54) Title: NOVEL HETEROARYL DERIVATIVES AND THE USE THEREOF AS PHARMACEUTICALS

(54) Bezeichnung: NEUE HETEROARYL-DERIVATE UND DEREN VERWENDUNG ALS ARZNEIMITTEL



(I)

(57) Abstract: The invention relates to novel heteroaryl derivatives of general formula (1), the production thereof and the use of the same as pharmaceuticals, especially for treating tumours.

(57) Zusammenfassung: Die Erfindung betrifft neue Heteroaryl-Derivate der allgemeinen Formel (1), deren Herstellung und Verwendung als Arzneimittel, insbesondere zur Behandlung von Tumoren.

WO 02/08192 A1

IN THE MATTER OF an Australian
Application corresponding to
PCT Application PCT/EP01/08261

RWS Group plc, of Europa House, Marsham Way, Gerrards Cross, Buckinghamshire, England, hereby solemnly and sincerely declares that, to the best of its knowledge and belief, the following document, prepared by one of its translators competent in the art and conversant with the English and German languages, is a true and correct translation of the PCT Application filed under No. PCT/EP01/08261.

Date: 8 November 2002

S. ANTHONY
Director
For and on behalf of RWS Group plc

Novel heteroaryl derivatives and their use as medicaments

The invention relates to novel heteroaryl derivatives of the formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.

According to a first aspect of the invention there is provided quinoline derivatives of the formula 1



formula 1

in which

R, R_1, R_2, R_3 can be attached to any of the quinoline carbon atoms C_2 to C_8, are identical or different and independently of one another denote hydrogen, straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, straight-chain or branched (C_1-C_8)-alkylcarbonyl, preferably acetyl, straight-chain or branched (C_1-C_8)-alkoxy, halogen, aryl-(C_1-C_8)-alkoxy, preferably benzyloxy or phenylethyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, (C_1-C_8)-alkoxycarbonylamino, (C_1-C_6)-alkoxycarbonylamino-(C_1-C_8)-alkyl, cyano, straight-chain or branched cyano-(C_1-C_6)-alkyl, carboxyl, (C_1-C_8)-alkoxycarbonyl, (C_1-C_4)-alkyl which is substituted by one or more fluorine atoms, preferably the trifluoromethyl group, carboxy-(C_1-C_8)-alkyl or (C_1-C_8)-alkoxycarbonyl-(C_1-C_6)-alkyl, (C_2-

C_6)-alkenyl, preferably allyl, (C_2-C_6)-alkynyl, preferably ethynyl or propargyl, straight-chain or branched cyano-(C_1-C_6)-alkyl, preferably cyanomethyl, aryl, where the aryl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of halogen, straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, carboxyl, straight-chain or branched (C_1-C_8)-alkoxycarbonyl, preferably tert-butoxy-carbonyl, by trifluoromethyl, hydroxyl, straight-chain or branched (C_1-C_8)-alkoxy, preferably methoxy or ethoxy, benzyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, cyano, straight-chain or branched cyano-(C_1-C_6)-alkyl, where additionally R and R_1 or R_2 and R_3 may form a fused aromatic 6-membered ring with the quinoline ring forming an acridine ring which for its part may be substituted at any C atom ring position by the radicals R, R_1, R_2 and R_3 having the meanings mentioned above;

Z is oxygen or sulfur, where the radical



substituted on the quinoline heterocycle may be attached to C atoms C_2-C_8 of the quinoline ring skeleton;

P, Q independently of one another represent oxygen or in each case two hydrogen atoms (i.e. -CH_2-);

X is nitrogen;

n and m independently of one another denotes an integer between 0-3, with the proviso that when n = 0, X denotes a CR_5R_6 group where R_5 and R_6 independently of one another represent hydrogen or (C_1-C_6)-alkyl and that the nitrogen atom adjacent to the C=Z group is substituted by a hydrogen atom or a (C_1-C_6)-alkyl group;

R_4 denotes a straight-chain or branched (C_1-C_{20})-alkyl radical which may be saturated or unsaturated, with one to three double and/or triple bonds, and which may be unsubstituted or may optionally be substituted at the same or different C atoms by one, two or more aryl, heteroaryl, halogen, cyano, (C_1-C_6)-alkoxy-carbonylamino, (C_1-C_6)-alkoxy, amino, mono-(C_1-C_4)-alkylamino or di-(C_1-C_4)-alkylamino; a (C_6-C_{14})-aryl radical, (C_6-C_{14})-aryl-(C_1-C_4)-alkyl radical or a (C_2-C_{10})-heteroaryl or (C_2-C_{10})-heteroaryl-(C_1-C_4)-alkyl radical which contains one or more heteroatoms selected from the group consisting of N, O and S, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and where the (C_6-C_{14})-aryl or (C_2-C_{10})-heteroaryl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, halogen, cyano, (C_1-C_6)-alkoxycarbonylamino, (C_1-C_6)-alkoxy, carboxyl, (C_1-C_8)-alkoxycarbonyl, straight-chain or branched (C_1-C_6)-alkyl which is substituted by one or more fluorine atoms, preferably trifluoromethyl, hydroxyl, straight-chain or branched (C_1-C_8)-

alkoxy, preferably methoxy or ethoxy, where adjacent oxygen atoms may also be linked by (C_1-C_2)-alkylene groups, preferably by a methylene group, benzyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, aryl, which for its part may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, carboxyl, straight-chain or branched (C_1-C_8)-alkoxycarbonyl, by trifluoromethyl, hydroxyl, straight-chain or branched (C_1-C_8)-alkoxy, preferably methoxy or ethoxy, benzyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, cyano, straight-chain or branched cyano-(C_1-C_6)-alkyl;

and their structural isomers and stereoisomers, in particular tautomers, diastereomers and enantiomers, and their pharmaceutically acceptable salts, in particular acid addition salts, are provided.

Thus, for example, the compounds of the formula (1) according to the invention which have one or more centers of chirality and which are present as racemates can be separated by methods known per se into their optical isomers, i.e. enantiomers or diastereomers. The separation can be carried out by column separation on chiral phases or by recrystallization from an optically active solvent or using an optically active acid or base or by derivatization with an optically active reagent, such as, for example, an optically active alcohol, and subsequent removal of the radical.

Furthermore, the quinoline derivatives of the formula (1) according to the invention can be converted into their salts with inorganic or organic acids, in particular, for pharmaceutical use, into their

physiologically acceptable salts. Acids which are suitable for this purpose are, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, acetic acid, tartaric acid, malic acid, embonic acid, malonic acid, trifluoroacetic acid or maleic acid.

Moreover, the compounds of the formula (1) according to the invention can, if they contain a sufficiently acidic group, such as a carboxyl group, be converted, if desired, into their salts with inorganic or organic bases, in particular, for pharmaceutical use, into their physiologically acceptable salts. Bases which are suitable for this purpose are, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, lysine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

According to a preferred embodiment, quinoline derivatives of the formula 1 are provided in which R, R1, R2, R3, X, Z, P, Q, n and m have the meanings given above and

R_4 denotes a straight-chain or branched (C_1-C_{20})-alkyl radical which may be saturated or unsaturated, with one to three double and/or triple bonds, and which may be unsubstituted or optionally substituted on the same or different C atoms by one, two or more aryl, heteroaryl, halogen, (C1-C6)-alkoxy, amino, mono-(C_1-C_4)-alkylamino or di-(C_1-C_4)-alkylamino;

a phenyl ring or a naphthyl ring, each of which may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, halogen, carboxyl, (C_1-C_8)-alkoxycarbonyl, straight-chain or

branched (C_1-C_6)-alkyl which is substituted by one or more fluorine atoms, preferably trifluoromethyl, hydroxyl, straight-chain or branched (C_1-C_8)-alkoxy, preferably methoxy or ethoxy, where adjacent oxygen atoms may also be linked by (C_1-C_2)-alkylene groups, preferably a methylene group, benzyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, aryl, which for its part may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, carboxyl, straight-chain or branched (C_1-C_8)-alkoxycarbonyl, by trifluoromethyl, hydroxyl, straight-chain or branched (C_1-C_8)-alkoxy, preferably methoxy or ethoxy, benzyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, cyano, straight-chain or branched cyano-(C_1-C_6)-alkyl;

a 2-, 4-, 5- or 6-pyrimidinyl radical or 2-, 4-, 5- or 6-pyrimidinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- [lacuna] polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4-, 5- or 6-pyrimidinyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 3-, 4-, 5- or 6-pyridazinyl radical or 3-, 4-, 5- or 6-pyridazinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- [lacuna] polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 3-, 4-, 5- or 6-pyridazinyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 5- or 6-pyrazinyl radical or 2-, 3-, 5- or 6-pyrazinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- [lacuna] polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 3-, 5- or 6-pyrazinyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical or 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- [lacuna] polysubstituted by

identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical may be unsubstituted or mono- to pentasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical or 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- [lacuna] polysubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen and oxo (=O) and the or [sic] 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical may be unsubstituted or mono- to pentasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical [lacuna] 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- [lacuna] polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the or [sic] 2-,

3-, 5-, 6-, 7-, or 8-quinoxalinyl radical may be unsubstituted or mono- to pentasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical or 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- [lacuna] polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the or [sic] 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical may be unsubstituted or mono- to pentasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical or 2-, 3-, 4-, 5-, 6-, 7 or 8-quinolyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical may be unsubstituted or mono- to hexasubstituted by identical or different

substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, preferably methyl, particularly preferably 2-methyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical or 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical may be unsubstituted or mono- to hexasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 6-, 8- or 9-[9*H*]-purinyl radical or 2-, 6-, 8- or 9-[9*H*]-purinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 6-, 8- or 9-[9*H*]-purinyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino,

mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 6-, 7- or 8-[7*H*]-purinyl radical or 2-, 6-, 7- or 8-[7*H*]-purinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 6-, 7- or 8-[7*H*]-purinyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical or 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl-(C_1-C_4)-alkyl radical, where the (C_1-C6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical may be unsubstituted or mono- to octasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono-

or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical or 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical may be unsubstituted or mono- to octasubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, (C_6-C_{10})-aryl-(C_1-C_6)-alkoxy, preferably benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 4-, 5- or 6-pyridyl radical where the 2-, 3-, 4-, 5- or 6-pyridyl radical may be unsubstituted or mono- to tetrasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 4-, 5- or 6-pyridinyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be

unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 3-, 4-, 5- or 6-pyridinyl radical may be unsubstituted or mono- to tetrasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 4- or 5-thienyl radical or 2-, 3-, 4- or 5-thienyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 3-, 4- or 5-thienyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 4-, or 5-thiazolyl radical or 2-, 4-, or 5-thiazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4-, or 5-thiazolyl radical may be unsubstituted or mono- or

disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 3-, 4-, or 5-isothiazolyl radical or 3-, 4-, or 5-isothiazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 3-, 4-, or 5-isothiazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical or 2-, 4-, 5-, 6-, or 7-benzothiazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical may be unsubstituted or mono- to tetrasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino,

hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 2-, 4-, or 5-imidazolyl radical or 1-, 2-, 4-, or 5-imidazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 2-, 4-, or 5-imidazolyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 3-, 4-, or 5-pyrazolyl radical or 1-, 3-, 4- or 5-pyrazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 3-, 4- or 5-pyrazolyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 2-, 3-, 4-, or 5-pyrrolyl radical or 1-, 2-, 3-, 4-, or 5-pyrrolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 2-, 3-, 4- or 5-pyrrolyl radical may be unsubstituted or mono- to tetrasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 3-, or 5-[1.2.4]-triazolyl radical or 1-, 3-, or 5-[1.2.4]-triazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 3-, or 5-[1.2.4]-triazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 4-, or 5-[1.2.3]-triazolyl radical or 1-, 4-, or 5-[1.2.3]-triazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be

unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 4-, or 5-[1.2.3]-triazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1- or 5-[1*H*]-tetrazolyl radical or 1-, or 5-[1*H*]-tetrazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, or 5-[1*H*]-tetrazolyl radical may be unsubstituted or substituted by hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2- or 5-[2*H*]-tetrazoyl radical or 2- or 5-[2*H*]-tetrazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2- or 5-[2*H*]-tetrazolyl radical may be unsubstituted or substituted by hydrogen, (C_1-C_6)-alkyl, halogen,

nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 4-, or 6-[1.3.5]-triazinyl radical or 2-, 4-, or 6-[1.3.5]-triazinyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4-, or 6-[1.3.5]-triazinyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 4-, or 5-oxazolyl radical or 2-, 4-, or 5-oxazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4-, or 5-oxazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino

or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 3-, 4-, or 5-isoxazolyl radical or 3-, 4-, or 5-isoxazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 3-, 4-, or 5-isoxazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical or 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical may be unsubstituted or mono- to hexasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, preferably trifluoromethyl, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl and the isomers, in particular tautomers, diastereomers and

enantiomers, and the pharmaceutically acceptable salts, in particular acid addition salts, thereof.

According to a further embodiment, quinoline derivatives of the formula (1) are provided which are characterised in that R, R_1, R_2, R_3, X, Z, P, Q, n and m have the meanings given above and R_4 represents phenyl which is unsubstituted or substituted by one to five identical or different (C_1-C_6)-alkoxy groups, where adjacent oxygen atoms may also be linked by (C_1-C_2)-alkylene groups.

According to a further embodiment, quinoline derivatives of the formula (1) are provided which are characterised in that R, R_1, R_2, R_3, X, Z, P, Q, n and m have the meanings given above and R_4 represents 3,5-dimethoxyphenyl.

According to a further embodiment, quinoline derivatives of the formula (1) are provided which are characterised in that R_4 has the meanings given above, R, R_1, R_2, R_3 each represent a hydrogen atom, Z represents an oxygen atom and X represents a nitrogen atom, P and Q each represent two hydrogen atoms (i.e. -CH2-), m is zero and n is the integer 2.

According to a further embodiment, quinoline derivatives of the formula (1) are provided which are characterised in that R, R_1, R_2, R_3 each represent a hydrogen atom, Z represents an oxygen atom, X represents a nitrogen atom, P and Q each represent two hydrogen atoms (i.e. -CH2-), m is zero, n represents the integer 2 and R_4 represents a 3,5-dimethoxyphenyl radical.

According to a second aspect of the invention, there is provided a process for preparing quinoline derivatives of formula (1) according to the first aspect of the invention which is characterised in that a quinoline carboxylic acid of the formula (2)



formula 2

in which R, R1, R2, R3 have the meanings given above, Z denotes an oxygen or sulfur atom and Y represents a leaving group such as halogen, hydroxyl, (C1-C6)-alkoxy, preferably methoxy or ethoxy, -O-tosyl, -O-mesyl or imidazolyl, is reacted with an amine of the formula (3)



formula 3

in which R4, X, P, Q, m and n are as defined above, using, if appropriate, diluents and auxiliaries, and the desired quinoline derivatives are formed.

Synthesis route:

The compounds of the formula 1 can be obtained according to Scheme 1 below:

Scheme 1



The starting materials (2) and (3) are either commercially available or can be prepared by procedures known per se. The starting materials (2) and (3) are useful intermediates for preparing the quinoline derivatives of the formula (1) according to the invention.

The solvents and auxiliaries to be used, if appropriate, and the reaction parameters to be used, such as reaction temperature and reaction time, are known to the person skilled in the art owing to his expert knowledge.

The quinoline derivatives of the formula (1) according to the invention are suitable as medicaments, in particular as antitumor agents, for treating mammals, in particular man, but also domestic animals such as horses, cattle, dogs, cats, hares, sheep, poultry and the like.

Accordingly, in a third aspect of the invention there is provided a medicament for the treatment of tumors comprising as active ingredient, at least one quinoline derivative of formula (1) according to the first aspect of the invention or a pharmaceutically acceptable salt thereof, if appropriate together with customary pharmaceutically acceptable auxiliaries, additives and carriers. These can be solid, semisolid, liquid or aerosol preparations. Suitable solid preparations are, for example, capsules, powders, granules, tablets. Suitable semisolid preparations are, for example, ointments, creams, gels, pastes, suspensions, oil-in-water and water-in-oil emulsions. Suitable liquid preparations are, for example, sterile aqueous preparations for parenteral administration which are isotonic with the blood of the patient.

According to a fourth aspect of the invention there is provided a method for treating tumors in mammals, in particular humans, the method comprising administering to said mammal at least one quinoline derivative of formula (1) according to the first aspect of the invention in a dose effective for tumor treatment, or a medicament according to the third aspect of the invention. The therapeutically effective dose of the quinoline derivative according to the invention in question which is to be administered for the treatment depends inter alia on the nature and the stage of the oncosis, the age and the sex of the patient, the type of administration and the duration of the treatment. Administration can take place orally, rectally, buccally (for example sublingually), parenterally (for example subcutaneously, intra-muscularly, intradermally or intravenously), topically or transdermally.

According to a fifth aspect of the invention there is provided the use of quinoline derivatives of formula (1) according to the first aspect of the invention for the preparation of a medicament for treating tumors in mammals.

According to a sixth aspect of the invention there is provided quinoline derivatives of formula (1) according to the first aspect of the invention when used as a medicament.

The invention is to be illustrated in more detail by the examples below, without being restricted to the examples.

Working Examples

Example 1

1-(3,5-dimethoxyphenyl)-4-(4-quinolyl-carbonyl)piperazine ("D-24203")

2 g (11.5 mmol) of quinoline-4-carboxylic acid were suspended in 80 ml of DMF. With stirring, 1.74 g (17.2 mmol) of N-methylmorpholine and then a solution of 8.95 g (17.2 mmol) of Py-BOP (1-benzotriazolyl-tripyrrolidinophosphonium hexafluorophosphate) and 2.56 g (11.5 mmol) of 1-(3,5-dimethoxyphenyl)piperazine in

25 ml of DMF were added to this mixture. The mixture was stirred at RT for 12 h, the DMF was distilled off under reduced pressure and the residue was purified on a silica gel column (Kieselgel 60, from Merck AG, Darmstadt) using the mobile phase dichloromethane/methanol/25 percent ammonia (90:10:1 v/v/v).

Yield: 3.4 g (78.3% of theory)

IR: ν = 3070, 2997, 2953, 2895, 2827, 1629, 1587, 1195, 1148, 991, 826 cm^{-1}

melting point: 146-148°C

mass spectrum: m/e = 378 (M^+)

^{1}H-NMR (DMSO) δ = 8.95 (d, 1H), 8.12 (d, 1H), 7.85 (m, 2H), 7.67 (t, 1H), 7.52 (d, 1H), 6.1 (s, 2H), 6.01 (s, 1H), 3.95 (br. s, 2H), 3.69 (s, 6H), 3.35 (m, 2H), 3.25-2.9 (m, 4H) ppm.

Example 2

[4-(3,5-Dimethoxyphenyl)piperazin-1-yl]quinolin-4-ylmethanone hydrochloride ("D-43589")

IR: ν = 3375, 2428, 1714, 1626, 1597, 1201, 1159, 843 cm^{-1}

melting point: 131-133°C

mass spectrum: m/e = 378 (M^+)

^{1}H-NMR (DMSO) δ= 9.32 (d, 1H), 8.47 (d, 1H), 8.18-7.9 (m, 4H), 6.4 (br. s, 1H), 4.05 (m, 2H), 3.72 (s, 6H), 3.54 (m, 2H), 3.42 (m, 2H), 3.26 (m, 1H), 3.07 (m, 1H) ppm.

Example 3

7-Chloro-2-(4-chlorophenyl)-6-methylquinolin-4-yl]-[4-(3,5-dimethoxyphenyl)-piperazin-1-yl]methanone ("D-68780")

IR: ν = 2933, 2834, 1626, 1610, 1582, 1251, 1150, 838 cm^{-1}

melting point: 226-228°C

mass spectrum: m/e = 537 (M^+)

^{1}H-NMR (DMSO) δ = 8.34 (d, 2H), 8.21 (d, 2H), 7.80 (s, 1H), 7.62 (d, 2H), 6.08 (s, 2H), 6.02 (s, 1H), 3.92 (s, 2H), 3.7 (s, 6H), 3.33-2.9 (m, 6H), 2.53 (s, 3H) ppm.

Example 4

[4-(3,5-Dimethoxyphenyl)piperazin-1-yl]-(3-hydroxy-2-methylquinolin-4-yl)methanone ("D-68675")

IR: ν = 3021, 2974, 2906, 2811, 1640, 1586, 1177, 813 cm^{-1}

melting point: 240°C

mass spectrum: m/e = 408 (M^+)

^{1}H-NMR (DMSO) δ = 9.95 (s, OH), 7.90 (d, 1H), 7.68-7.45 (m, 3H), 6.09 (s, 2H), 5.98 (s, 1H), 4.05 (m, 1H), 3.75 (m, 1H), 3.7 (s, 6H), 3.3-3.12 (m, 5H), 2.86 (m, 1H), 2.61 (s, 3H) ppm.

Example 5

[2-(3,4-Dimethoxyphenyl)-7-methylquinolin-4-yl]-[4-(3,5-dimethoxyphenyl)-piperazin-1-yl]methanone ("D-68823")

IR: ν = 2933, 2835, 1635, 1589, 1509, 1426, 1148, 994, 814 cm^{-1}

melting point: 92-94°C

mass spectrum: m/e = 528 (M^+)

^{1}H-NMR (DMSO) δ = 8.05 (s, 1H), 7.92-7.85 (m, 3H), 7.71 (d, 2H), 7.54 (d, 1H), 7.12 (d, 1H), 6.07 (s, 2H), 5.98 (s, 1H), 4.02 (m, 1H), 3.92 (s, 3H), 3.87 (s, 3H), 3.78 (m, 1H), 3.71 (s, 6H), 3.45-2.9 (m, 6H), 2.54 (s, 3H) ppm.

Example 6

[4-(6-Methylpyridin-2-yl)piperazin-1-yl]quinolin-4-ylmethanone ("D-85994")

mass spectrum: m/e = 333 (M^+)

^{1}H-NMR (DMSO) δ = 9.0 (s, 1H), 8.12 (d, 1H), 7.85 (dd, 2H), 7.68 (t, 1H), 7.54 (d, 1H), 7.45 (t, 1H), 6.62 (d, 1H), 6.55 (d, 1H), 4.0-3.8 (m, 2H), 3.73 (m, 2H), 3.45 (m, 2H), 3.22 (m, 2H), 2.30 (s, 3H) ppm.

Example 7

[4-(3-Methoxyphenyl)piperazin-1-yl]-(2-phenylquinolin-4-yl)methanone ("D-87197")

mass spectrum: m/e = 424 (M^+)

Example 8

[4-(6-Methylpyridin-2-yl)piperazin-1-yl]-(2-phenylquinolin-4-yl]methanone ("D-87130")

mass spectrum: m/e = 409 (M^+)

Example 9

[4-(3-Methoxyphenyl)piperazin-1-yl]quinolin-8-ylmethanone ("D-87219")

mass spectrum: m/e = 348 (M^+)

Example 10

(2-Phenylquinolin-4-yl)-(4-m-tolylpiperazin-1-yl)methanone ("D-87280")

mass spectrum: m/e= 408 (M^+)

Example 11

[4-(6-Chloropyridin-2-yl)piperazin-1-yl]-(2-phenylquinolin-4-yl)methanone ("D-87129")

mass spectrum: m/e = 429 (M^+)

1. Antiproliferative action in various tumor cell lines

In a proliferation test, the antiproliferative activity of the substance D-43411 was examined using established tumor cell lines. In the test used, the cellular dehydrogenation activity is determined, which makes it possible to determine the vitality of the cell and, indirectly, the cell count. The cell lines used are the human cervical carcinoma cell lines KB/HeLa (ATCC/CCL17), the murine lymphocyte leukaemia L1210 (ATCC CCL-219), the human breast adenocarcinoma line MCF7 /ATCC HTB22) and the ovary adenocarcinoma line SKOV-3 (ATCC HTB77). These are established cell lines which are very well characterized and were obtained from ATCC and cultured.

The results shown in Table 1 demonstrate the highly potent antiproliferative action of D-43411 in the cell lines SKOV-3, L-1210 and HeLa/KB. Owing to the particularly slow growth of the MCF7 line, the effect of D-43411 in the test period of 48 h is only small (18% inhibition at 3.16 µg/ml; thus stated as >3.16).

Table 1 In-vitro cytotoxicity in tumor cell lines (values determined from 5 substance concentrations)

Reference No.	Structure	MW	XTT - Assay IC_{50} [µg/ml]			
			SKOV-3	L1210	KB/HeLa	MCF7
D-43411		4.29	<0.0003	<0.0003	<0.0003	<3.16

2. Method

XTT Test for cellular dehydrogenase activity

The adherently growing tumor cell lines HeLa/KB, SKOV-3 and MCF7 and the L1210 leukaemia line, which grows in suspension, were cultivated under standard conditions in an incubator with gas inlet at 37°C, 5% CO_2 and 95% atmospheric humidity. On Test Day 1, the adherent cells are detached using trypsine/EDTA and pelleted by centrifugation. The cell pellet is then resuspended in RPMI culture medium at the appropriate cell count and transferred to a 96-well microtitre plate. The plates are then cultivated overnight in the incubator with gas inlet. The test substances are made up as stock solutions in DMSO and, on Test Day 2, diluted with culture medium to the desired concentrations. The

substances in the culture medium are then added to the cells and incubated in the incubator with gas inlet for 45 h. Cells which have not been treated with test substance serve as control.

For the XTT assay, 1 mg/ml of XTT (sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzenesulfonic acid) is dissolved in RPMI-1640 medium without Phenol Red. Additionally, a 0.383 mg/ml solution of PMS (N-methyldibenzopyrazine methyl sulfate) in phosphate-buffered saline (PBS) is prepared. On Test Day 4, 75 µl/well of the XTT-PMS mixture are pipetted onto the cell plates, which by now have been incubated with the test substances for 45 h. To this end, the XTT solution is mixed with the PMS solution in a ratio of 50:1 (v/v) shortly before use. The cell plates are then incubated in the incubator with gas inlet for a further 3 h, and the optical density (OD_{490nm}) is determined in a photometer.

Using the OD_{490nm} obtained, the inhibition in percent relative to the control is calculated. The antiproliferative activity is estimated using regression analysis.

Example I

Tablet containing 50 mg of active compound

Composition:

(1)	Active compound	50.0 mg
(2)	Lactose	98.0 mg
(3)	Maize starch	50.0 mg
(4)	Polyvinylpyrrolidone	15.0 mg
(5)	Magnesium stearate	2.0 mg
Total:		215.0 mg

Preparation:

(1), (2) and (3) are mixed and granulated with an aqueous solution of (4). The dried granules are admixed with (5). This mixture is tabletted.

Example II

Capsule containing 50 mg of active compound

Composition:

(1)	Active compound	50.0 mg
(2)	Maize starch, dried	58.0 mg
(3)	Lactose powder	50.0 mg
(4)	Magnesium stearate	2.0 mg
Total:		160.0 mg

Preparation:

(1) is ground with (3). This ground material is added with vigorous mixing to the mixture of (2) and (4). This powder mixture is, on a capsule filling machine, filled into hard gelatine capsules size 3.

The claims defining the invention are as follows:

1. Quinoline derivatives according to the formula 1



formula 1

in which

R, R_1, R_2, R_3 can be attached to any of the quinoline carbon atoms C_2 to C_8, are identical or different and independently of one another denote hydrogen, straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, straight-chain or branched (C_1-C_8)-alkylcarbonyl, straight-chain or branched (C_1-C_8)-alkoxy, halogen, aryl-(C_1-C_8)-alkoxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, (C_1-C_8)-alkoxycarbonylamino, (C_1-C_6)-alkoxycarbonylamino-(C_1-C_8)-alkyl, cyano, straight-chain or branched cyano-(C_1-C_6)-alkyl, carboxyl, (C_1-C_8)-alkoxycarbonyl, (C_1-C_4)-alkyl which is substituted by one or more fluorine atoms, carboxy-(C_1-C_8)-alkyl or (C_1-C_8)-alkoxycarbonyl-(C_1-C_6)-alkyl, (C_2-C_6)-alkenyl, (C_2-C_6)-alkynyl, straight-chain or branched cyano-(C_1-C_6)-alkyl, aryl, where the aryl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of halogen, straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, carboxyl, straight-chain or branched (C_1-C_8)-alkoxycarbonyl, trifluoromethyl, hydroxyl, straight-chain or branched (C_1-C_8)-alkoxy, benzyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, cyano, straight-chain or branched cyano-(C_1-C_6)-alkyl,

wherein additionally R and R_1 or R_2 and R_3 may form a fused aromatic 6-membered ring with the quinoline ring forming an acridine ring which for its part may be substituted at any C atom ring position by the radicals R, R_1, R_2 and R_3 having the meanings mentioned above;

Z is oxygen or sulfur,

wherein the radical



substituted on the quinoline heterocycle may be attached to C atoms C_2-C_8 of the quinoline ring skeleton;

P and Q independently represent O or two hydrogen atoms;

X is nitrogen;

n and m independently of one another denotes an integer between 0-3, with the proviso that when n = 0, X denotes a CR_5R_6 group where R_5 and R_6 independently of one another represent hydrogen or (C_1-C_6)-alkyl and that the nitrogen atom adjacent to the C=Z group is substituted by a hydrogen atom or a (C_1-C_6)-alkyl group;

R_4 denotes a straight-chain or branched (C_1-C_{20})-alkyl radical which may be saturated or unsaturated, with one to three double and/or triple bonds, and which may be unsubstituted or may optionally be substituted at the same or different C atoms by one, two or more aryl, heteroaryl, halogen, cyano, (C_1-C_6)-alkoxy-carbonylamino, (C_1-C_6)-alkoxy, amino, mono-(C_1-C_4)-alkylamino or di-(C_1-C_4)-alkylamino; a (C_6-C_{14})-aryl radical, (C_6-C_{14})-aryl-(C_1-C_4)-alkyl radical or a (C_2-C_{10})-heteroaryl or (C_2-C_{10})-heteroaryl-(C_1-C_4)-alkyl radical which contains one or more heteroatoms selected from the group consisting of N, O and S, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and where the (C_6-C_{14})-aryl or (C_2-C_{10})-heteroaryl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, halogen, cyano, (C_1-C_6)-alkoxycarbonylamino, (C_1-C_6)-alkoxy, carboxyl, (C_1-C_8)-alkoxycarbonyl, straight-chain or branched (C_1-C_6)-alkyl which is substituted by one or more fluorine atoms, hydroxyl, straight-chain or branched (C_1-C_8)-alkoxy, where adjacent oxygen atoms may also be linked by (C_1-C_2)-alkylene groups, benzyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, aryl, which for its part may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, carboxyl, straight-chain or branched (C_1-C_8)-alkoxycarbonyl, trifluoromethyl, hydroxyl, straight-chain or branched (C_1-C_8)-alkoxy, benzyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, cyano, straight-chain or branched cyano-(C_1-C_6)-alkyl;

and their structural isomers and stereoisomers, and their pharmaceutically acceptable salts.

2. Quinoline derivatives of formula 1 according to claim 1, where R, R_1, R_2, R_3, X, Z, P, Q, n and m have the meanings given in claim 1 and

R_4 denotes a straight-chain or branched (C_1-C_{20})-alkyl radical which may be saturated or unsaturated, with one to three double and/or triple bonds, and which may be unsubstituted or optionally substituted on the same or different C atoms by one, two or more aryl, heteroaryl, halogen, (C_1-C_6)-alkoxy, amino, mono-(C_1-C_4)-alkylamino or di-(C_1-C_4)-alkylamino;

a phenyl ring or a naphthyl ring, each of which may be unsubstituted or mono- or poly-substituted by identical or different substituents from the group consisting of straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, halogen, cyano, (C_1-C_6)-alkoxycarbonylamino, (C_1-C_6)-alkoxy, carboxyl, (C_1-C_8)-alkoxycarbonyl, straight-chain or branched (C_1-C_6)-alkyl which is substituted by one or more fluorine atoms, hydroxyl, straight-chain or branched (C_1-C_8)-alkoxy, benzyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, aryl, which for its part may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of straight-chain or branched (C_1-C_8)-alkyl, (C_3-C_7)-cycloalkyl, carboxyl, straight-chain or branched (C_1-C_8)-alkoxycarbonyl, trifluoromethyl, hydroxyl, straight-chain or branched (C_1-C_8)-alkoxy, benzyloxy, nitro, amino, mono-(C_1-C_4)-alkylamino, di-(C_1-C_4)-alkylamino, cyano, straight-chain or branched cyano-(C_1-C_6)-alkyl;

a 2-, 4-, 5- or 6-pyrimidinyl radical or 2-, 4-, 5- or 6-pyrimidinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4-, 5- or 6-pyrimidinyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonyl-amino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 3-, 4-, 5- or 6-pyridazinyl radical or 3-, 4-, 5- or 6-pyridazinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 3-, 4-, 5- or 6-pyridazinyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonyl-amino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 5- or 6-pyrazinyl radical or 2-, 3-, 5- or 6-pyrazinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 3-, 5- or 6-pyrazinyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical or 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical may be unsubstituted or mono- to pentasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical or 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical may be unsubstituted or mono- to pentasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical or 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical may be unsubstituted or mono- to pentasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-

C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonyl-amino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical or 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical may be unsubstituted or mono- to pentasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical or 2-, 3-, 4-, 5-, 6-, 7 or 8-quinolyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical may be unsubstituted or mono- to hexasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical or 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical may be unsubstituted or mono- to hexasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 6-, 8- or 9-[9*H*]-purinyl radical or 2-, 6-, 8- or 9-[9*H*]-purinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 6-, 8- or 9-(9*H*)-purinyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-

alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonyl-amino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 6-, 7- or 8-[7*H*]-purinyl radical or 2-, 6-, 7- or 8-[7*H*]-purinyl-(C_1-C_4)-alkyl radical, where the (C_1-C_4)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 6-, 7- or 8-(7*H*)-purinyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonyl-amino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical or 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical may be unsubstituted or mono- to octasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical or 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical may be unsubstituted or mono- to octasubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, (C_6-C_{10})-aryl-(C_1-C_6)-alkoxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 4-, 5- or 6-pyridyl radical where the 2-, 3-, 4-, 5- or 6-pyridyl radical may be substituted or mono- or tetrasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl,

(C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 4-, 5-, or 6-pyridinyl (C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 3-, 4-, 5-, or 6-pyridinyl radical may be unsubstituted or mono- to tetrasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 3-, 4-, or 5-thienyl radical, or 2-, 3-, 4- or 5-thienyl- (C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 3-, 4- or 5-thienyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 4-, or 5-thiazolyl radical, or 2-, 4- or 5-thiazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4- or 5-thiazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 3-, 4-, or 5-isothiazolyl radical, or 3-, 4- or 5-isothiazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 3-, 4- or 5-isothiazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino,

hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical, or 2-, 4-, 5-, 6-, or 7-benzothiazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical may be unsubstituted or mono- to tetrasubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 2-, 4-, or 5-imidazolyl radical, or 1-, 2-, 4-, or 5-imidazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 2-, 4-, or 5-imidazolyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 3-, 4-, or 5-pyrazolyl radical, or 1-, 3-, 4-, or 5-pyrazolyl-(C_1-C_6)-alkyl radical, where the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 3-, 4-, or 5-pyrazolyl radical may be unsubstituted or mono- to trisubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 2-, 3-, 4-, or 5-pyrrolyl radical, or 1-, 2-, 3-, 4-, or 5-pyrrolyl-(C_1-C_6)-alkyl radical, wherein the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 2-, 3-, 4-, or 5-pyrrolyl radical may be unsubstituted or mono- to tetrasubstituted by identical or different substituents from the

group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 3-, or 5-[1.2.4]-triazolyl radical, or 1-, 3-, or 5-[1.2.4]-triazolyl-(C_1-C_6)-alkyl radical, wherein the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 3-, or 5-[1.2.4]-triazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 4-, or 5-[1.2.3]-triazolyl radical, or 1-, 4-, or 5-[1.2.3]-triazolyl-(C_1-C_6)-alkyl radical, wherein the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 4-, or 5-[1.2.3]-triazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1- or 5-[1*H*]-tetrazolyl radical or 1- or 5-[1*H*]-tetrazolyl-(C_1-C_6)-alkyl radical, wherein the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1- or 5-[1*H*]-tetrazolyl radical may be unsubstituted or substituted by hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonyl-amino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2- or 5-[2*H*]-tetrazolyl radical or 2- or 5-[2*H*]-tetrazolyl-(C_1-C_6)-alkyl radical, wherein the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2- or 5-[2*H*]-tetrazolyl radical may be unsubstituted or substituted by hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-

alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 4-, or 6-[1.3.5]-triazinyl radical, or 2-, 4-, or 6-[1.3.5]-triazinyl-(C_1-C_6)-alkyl radical, wherein the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4-, or 6-[1.3.5]-triazinyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 2-, 4-, or 5-oxazolyl radical, or 2-, 4-, or 5-oxazolyl-(C_1-C_6)-alkyl radical, wherein the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 2-, 4-, or 5-oxazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 3-, 4-, or 5-isoxazolyl radical, or 3-, 4-, or 5-isoxazolyl-(C_1-C_6)-alkyl radical, wherein the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 3-, 4-, or 5-isoxazolyl radical may be unsubstituted or mono- or disubstituted by identical or different substituents from the group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl;

a 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical or 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl-(C_1-C_6)-alkyl radical, wherein the (C_1-C_6)-alkyl radical may be unsubstituted or mono- or polysubstituted by identical or different substituents from the group consisting of (C_1-C_6)-alkyl, halogen and oxo (=O) and the 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical may be unsubstituted or mono- to hexasubstituted by identical or different substituents from the

group consisting of hydrogen, (C_1-C_6)-alkyl, halogen, nitro, amino, mono-(C_1-C_6)-alkylamino, di-(C_1-C_6)-alkylamino, hydroxyl, (C_1-C_6)-alkoxy, benzyloxy, carboxyl, (C_1-C_6)-alkoxycarbonyl, (C_1-C_6)-alkoxycarbonylamino or (C_1-C_6)-alkyl which is mono- or polysubstituted by fluorine, (C_6-C_{10})-aryl and (C_6-C_{10})-aryl-(C_1-C_6)-alkyl.

2. Quinoline derivatives according to claim 1, wherein said aryl-(C_1-C_8)-alkoxy group is benzyloxy or phenylethyloxy.

3. Quinoline derivatives according to claim 1, wherein said (C_1-C_8)-alkylcarbonyl group is acetyl.

4. Quinoline derivatives according to claim 1, wherein said (C_1-C_4)-alkyl groups substituted by one or more fluorine atoms is a trifluoromethyl group.

5. Quinoline derivatives according to claim 1, wherein said (C_2-C_6)-alkenyl group is allyl.

6. Quinoline derivatives according to claim 1, wherein said (C_2-C_6)-alkynyl group is ethynyl or propargyl.

7. Quinoline derivatives according to claim 1, wherein said cyano-(C_1-C_6)-alkyl group is cyanomethyl.

8. Quinoline derivatives according to claim 1, wherein said branched (C_1-C_8)-alkoxycarbonyl group is tert-butoxycarbonyl.

9. Quinoline derivatives according to claim 1, wherein said (C_1-C_2)-alkylene groups linking adjacent oxygen atoms is a methylene group.

10. Quinoline derivatives according to claim 1, wherein said structural isomers and stereoisomers are tautomers, diastereomers or enantiomers.

11. Quinoline derivatives according to claim 1, wherein said salts are acid addition salts.

12. Quinoline derivatives according to claim 1 or 2, wherein one or more of said said (C_1-C_8)-alkoxy group(s) is methoxy or ethoxy.

13. Quinoline derivatives according to claim 1 or 2, wherein one or more of said (C_1-C_6)-alkyl group which is substituted by one or more fluorine atoms is trifluoromethyl.

14. Quinoline derivatives according to claim 2, wherein one or more of said (C_1-C_6)-alkyl substituents on the 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical is methyl.

15. Quinoline derivatives according to claim 2, wherein one or more of said (C_1-C_6)-alkyl substituents on the 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical is 2-methyl.

16. Quinoline derivatives according to claim 2, wherein one or more of said (C_6-C_{10})-aryl-(C_1-C_6)-alkoxy substituents on the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical is benzyloxy.

17. Quinoline derivatives according to any one of claims 1 to 16, wherein R, R_1, R_2, R_3, X, Z, P, Q, n and m have the meanings given above and R_4 represents phenyl which is unsubstituted or substituted by one to five identical or different (C_1-C_6)-alkoxy groups, where adjacent oxygen atoms may also be linked by (C_1-C_2)-alkylene groups.

18. Quinoline derivatives according to any one of claims 1 to 17, wherein R, R_1, R_2, R_3, X, Z, P, Q, n and m have the meanings given above and R_4 represents 3,5-dimethoxyphenyl.

19. Quinoline derivatives according to any one of claims 1 to 18, wherein R_4 has the meanings given above, R, R_1, R_2, R_3 each represents a hydrogen, Z represents an oxygen atom, X represents a nitrogen atom, P and Q each represent two hydrogen atoms (i.e. -CH_2-), m is zero, and n is 2.

20. Quinoline derivatives according to any one of claims 1 to 19, wherein R, R_1, R_2, R_3 each represent a hydrogen atom, Z represents an oxygen atom, X represents a nitrogen atom, P and Q each represent two hydrogen atoms (i.e. -CH_2-), m is zero, n is 2, and R_4 represents a 3,5-dimethoxyphenyl radical.

21. A quinoline derivative of formula 1 as defined in claim 1, substantially as hereinbefore described with reference to Example 1.

22. Quinoline derivatives according to any one of claims 1 to 21 when used as a medicament.

23. A medicament comprising as active ingredient, at least one quinoline derivative according to any one of claims 1 to 21, if appropriate together with customary pharmaceutically acceptable auxiliaries, additives and carriers.

24. Use of the quinoline derivatives according to any one of claims 1 to 21 for the preparation of a medicament for treating tumors in mammals.

25. A method for treating tumors in mammals, said method comprising administering to said mammal at least one quinoline derivative according to any one of claims 1 to 21 in a dose effective for tumor treatment, or a medicament according to claim 23.

26. A process for preparing quinoline derivatives according to any one of claims 1 to 20, wherein a quinoline carboxylic acid of the formula (2)



formula 2

in which R, R_1, R_2, R_3 have the meanings given above, Z denotes an oxygen or sulfur atom and Y represents a leaving group such as halogen, hydroxyl, (C_1-C_6)-alkoxy, -O-tosyl, -O-mesyl or imidazolyl, is reacted with an amine of the formula (3)



formula 3

in which R_4, X, P, Q, m and n have the meanings given above, if appropriate using diluents and auxiliaries, and the desired quinoline derivatives are formed.

27. The process according to claim 26, wherein said (C_1-C_6)-alkoxy group is methoxy or ethoxy.

28. A process for preparing quinoline derivatives of formula (I) as defined in claim 1, substantially as hereinbefore described with reference to Example 1.

29. A quinoline derivative of formula (I) prepared according to the process of any one of claims 26 to 28.

Dated 21 April, 2005
Zentaris GmbH

Patent Attorneys for the Applicant/Nominated Person
SPRUSON & FERGUSON